Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study
Open Access
- 1 January 2012
- journal article
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 9 (1) , 32
Abstract
Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes dyslipidaemia. There are contradictory data regarding the association between lopinavir concentrations and changes in lipids.Keywords
This publication has 22 references indexed in Scilit:
- Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir TabletsAntimicrobial Agents and Chemotherapy, 2011
- The protease inhibitor combination lopinavir/ritonavir does not decrease insulin secretion in healthy, HIV-seronegative volunteersAIDS, 2010
- Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug ActionClinical Pharmacokinetics, 2010
- No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavir‐Ritonavir in Healthy Subjects without HIV Infection: A Placebo‐Controlled TrialClinical Infectious Diseases, 2008
- Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected PatientsDiabetes Care, 2008
- Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analoguesJournal of Antimicrobial Chemotherapy, 2007
- Single‐Dose Lopinavir‐Ritonavir Acutely Inhibits Insulin‐Mediated Glucose Disposal in Healthy VolunteersClinical Infectious Diseases, 2006
- Predictive Factors of Hyperlipidemia in HIV-Infected Subjects Receiving Lopinavir/RitonavirAIDS Research and Human Retroviruses, 2006
- LopinavirDrugs, 2000
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998